Literature DB >> 16169277

Critical function of the CD40 pathway in parvovirus B19 infection revealed by a hypomorphic CD40 ligand mutation.

Frank Blaeser1, Michael Kelly, Karen Siegrist, Gregory A Storch, Richard S Buller, Jessica Whitlock, Nga Truong, Talal A Chatila.   

Abstract

Parvovirus B19-induced chronic anemia has been associated with failure to mount an effective neutralizing antibody response. We describe an adolescent male with a 13-year history of parvovirus B19-induced anemia as the primary manifestation of X-linked hyper IgM immunodeficiency (XHIM). This patient, whose serum IgG concentration was at the low end of the normal range and who mounted IgG antibody responses to T cell-dependent antigens, suffered from a nonsense mutation (R11 --> X) in the CD40 ligand (CD40L) gene. This resulted in low-level expression of a mutant CD40L predicted to lack the cytoplasmic domain. Intravenous immunoglobulin therapy alone or in combination with interferon gamma, given in the context of impaired Th1 cytokine production, suppressed but did not eradicate the infection. These results highlight the critical function of the CD40/CD40L pathway in parvovirus B19 infection and suggest that subtle defects in this pathway may underlie cases of chronic parvovirus B19 infection atypical of XHIM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169277     DOI: 10.1016/j.clim.2005.08.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  Phenotypic heterogeneity in a family with a CD40 ligand intracellular domain mutation.

Authors:  S Kiani-Alikhan; P F K Yong; K C Gilmour; D Grosse-Kreul; E G Davies; M A A Ibrahim
Journal:  J Clin Immunol       Date:  2011-10-19       Impact factor: 8.317

2.  Persistent pure red cell aplasia in dicygotic twins with persistent congenital parvovirus B19 infection-remission following high dose intravenous immunoglobulin.

Authors:  Alice Lejeune; Malte Cremer; Horst von Bernuth; Anke Edelmann; Susanne Modrow; Christoph Bührer
Journal:  Eur J Pediatr       Date:  2014-10-02       Impact factor: 3.183

3.  Seroprevalence of human parvovirus B19 in healthy blood donors.

Authors:  Satish Kumar; R M Gupta; Sourav Sen; R S Sarkar; J Philip; Atul Kotwal; S H Sumathi
Journal:  Med J Armed Forces India       Date:  2013-02-23

Review 4.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

5.  Variants Disrupting CD40L Transmembrane Domain and Atypical X-Linked Hyper-IgM Syndrome: A Case Report With Leishmaniasis and Review of the Literature.

Authors:  Boaz Palterer; Lorenzo Salvati; Manuela Capone; Valentina Mecheri; Laura Maggi; Alessio Mazzoni; Lorenzo Cosmi; Nila Volpi; Lucia Tiberi; Aldesia Provenzano; Sabrina Giglio; Paola Parronchi; Giandomenico Maggiore; Oreste Gallo; Alessandro Bartoloni; Francesco Annunziato; Lorenzo Zammarchi; Francesco Liotta
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

6.  CD40 ligand deficiency: neurologic sequelae with radiographic correlation.

Authors:  Shrinivas Bishu; Deepak Madhavan; Phillip Perez; Lucy Civitello; Shuying Liu; Margaret Fessler; Steven M Holland; Ashish Jain; Maryland Pao
Journal:  Pediatr Neurol       Date:  2009-12       Impact factor: 3.372

7.  Clinical follow-up of 11 Argentinian CD40L-deficient patients with 7 unique mutations including the so-called "milder" mutants.

Authors:  Silvia Danielian; Matias Oleastro; Maria Eva Rivas; Claudio Cantisano; Marta Zelazko
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.542

8.  A Novel de Novo Mutation in the CD40 Ligand Gene in a Patient With a Mild X-Linked Hyper-IgM Phenotype Initially Diagnosed as CVID: New Aspects of Old Diseases.

Authors:  Tábata T França; Luiz F B Leite; Tiago A Maximo; Christiane G Lambert; Nuria B Zurro; Wilma C N Forte; Antonio Condino-Neto
Journal:  Front Pediatr       Date:  2018-05-04       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.